



## Annex Y

### Details of Pfizer Allocation Process

Throughout the last few weeks, the COVID-19 vaccine delivery endeavour across the world has proven extremely dynamic. Indeed, new developments came to light as the first wave review was proceeding and which have, as a result, affected decision-making. These have included:

- Pfizer requirements being more stringent than anticipated, with additional guarantees sought both in terms of indemnification & liability as well as from a programmatic readiness & supply handling perspective; these requirements may in turn pose a significant hurdle for some Participants, leading to potential delays in shipment
- Larger volumes of AstraZeneca doses through Serum Institute of India and SK Bioscience could become available via COVAX after mid-February, depending on when WHO Emergency Use Listing (EUL) is obtained; this timeline may coincide with Pfizer timelines

In the context of these new developments, and given the limited number of Pfizer doses available, the large number of Participants having expressed an interest in the Pfizer vaccine and their level of readiness, a decision was made to limit the number of Participants for this first delivery out of COVAX in order to enable a successful distribution and delivery. Building on the principles of fairness, transparency, and equity, we have divided all Participants by regional bloc – as per the six WHO regions – and by their Participant status – Self-Financing Participants and AMC Participants. Within each bloc, WHO has prioritized at least one Participant, based on COVID-19 epidemiological data (mortality, incidence rates and trends), for this first wave. Additionally, it was stipulated that Participants that initiated their COVID vaccination programme as of 28 January will not be included in the first wave Pfizer BNT162b2 vaccine.

Given the exceptional nature of this first wave allocation, the Independent Allocation of Vaccines Group (IAVG) was not leveraged, but all future allocation rounds will follow our standard approach. In total, 18 Participants have been included.